Filing Flows › Comparisons › MIST vs MREO
Milestone Pharmaceuticals vs Mereo BioPharma Group: MIST and MREO compared
Milestone Pharmaceuticals is the larger company: $559K of revenue in its latest quarter (Q2 2026) against $500K for Mereo BioPharma Group (Q2 2025).
Where the money goes: MIST and MREO
Milestone Pharmaceuticals (MIST) · Q2 2026
Milestone Pharmaceuticals, Q2 2026: revenue $559K, net loss $28.6M, operating cash flow −$22.7M. The chart follows the revenue to costs, profit and cash.
Mereo BioPharma Group (MREO) · Q2 2025
Mereo BioPharma Group, Q2 2025: revenue $500K, net loss $14.6M, operating cash flow −$7.7M. The chart follows the revenue to costs, profit and cash.
| Milestone Pharmaceuticals (MIST) | Mereo BioPharma Group (MREO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2025 |
| Revenue | $559K | $500K |
| Operating margin | n/m | n/m |
| Net earnings | −$28.6M | −$14.6M |
| Operating cash flow | −$22.7M | −$7.7M |
Questions
Which is bigger, Milestone Pharmaceuticals or Mereo BioPharma Group?
Milestone Pharmaceuticals is the larger company: $559K of revenue in its latest quarter (Q2 2026) against $500K for Mereo BioPharma Group (Q2 2025).
More: Milestone Pharmaceuticals earnings · how Milestone Pharmaceuticals makes money · Mereo BioPharma Group earnings · how Mereo BioPharma Group makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 12, 2025). Fiscal quarters can end on different dates. Not investment advice.